[go: up one dir, main page]

KR860000867A - 급성 방사선 증후군 발현억제 및 패혈증 발현억제의 방법 및 그 조성물 - Google Patents

급성 방사선 증후군 발현억제 및 패혈증 발현억제의 방법 및 그 조성물 Download PDF

Info

Publication number
KR860000867A
KR860000867A KR1019850004992A KR850004992A KR860000867A KR 860000867 A KR860000867 A KR 860000867A KR 1019850004992 A KR1019850004992 A KR 1019850004992A KR 850004992 A KR850004992 A KR 850004992A KR 860000867 A KR860000867 A KR 860000867A
Authority
KR
South Korea
Prior art keywords
composition
warm
effective amount
nmole
sepsis
Prior art date
Application number
KR1019850004992A
Other languages
English (en)
Other versions
KR880000191B1 (ko
Inventor
어니스트 리비 에드가
Original Assignee
원본미기재
리비 이뮤노켐 리써어치 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 리비 이뮤노켐 리써어치 인코포레이티드 filed Critical 원본미기재
Publication of KR860000867A publication Critical patent/KR860000867A/ko
Application granted granted Critical
Publication of KR880000191B1 publication Critical patent/KR880000191B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

내용 없음

Description

급성 방사선 증후군 발현억제 및 패혈증 발현억제의 방법 및 그 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 전몸체 X선 선량 100래드이상에 온혈동물이 노출됨으로써 생기는 온혈동물의 급성 방사선 증후군의 발현을 억제하는 방법에 있어서, ㄱ) 검출할 수 있는 양의 2-케토-3-데옥시옥타노 에이트, 인 약 350 내지 475 nmole/mg 및 지방산 약 1700 약 200 nmole/mg을 함유하는 정제 해독된 내독소와, ㄴ)제약상 허용되는 담체로 이루어지는 조성물의 유효량을 상기 X선 조사전에 온혈동물에 투여하는 것으로 되어 있는 것을 특징으로 하는 방법.
  2. 제1항에 있어서, 조성물이 인산염 완충생리식염수의 형태인 것을 특징으로 하는 방법.
  3. 제1항에 있어서, 조성물이 비경구적으로 투여되는 것을 특징으로 하는 방법.
  4. 제1항에 있어서, 조성물의 상기 유효량은 약 1 내지 1000㎍인 것을 특징으로 하는 방법.
  5. 제4항에 있어서, 상기 조성물의 유효량은 약 25내지 200㎍인 것을 특징으로 하는 방법.
  6. ㄱ)검출할 수 없는 양의 2-케토-3-데옥시옥타노에이트, 인 약 350내지 475nmole/mg 및 지방산 약 1700내지 2000nmole/mg 을 함유하는 정제 해독된 내독소와, ㄴ)제약상 허용되는 담체로 이루어지는 조성물의 유효량을 온혈동물에 투여하는 것으로 되어 있는 것을 특징으로 하는 온혈동물의 패혈증 발현억제의 방법.
  7. 제6항에 있어서, 조성물이 인산염 완충 생리식염수 용액의 형태인 것을 특징으로 하는 방법.
  8. 제6항에 있어서, 상기 조성물이 비경구적으로 투여되는 것을 특징으로 하는 방법.
  9. 제6항에 있어서, 조성물의 상기 유효량이 1내지 1000㎍인 것을 특징으로 하는 방법.
  10. 제9항에 있어서, 조성물의 상기 유효량이 약 25내지 200㎍인 것을 특징으로 하는 방법.
  11. (i) 전몸체 X선 선량 100래드이상에 온혈동물에 노출됨으로써 생기는 온혈동물의 급성방사선 증후군의 발현을 억제할 수 있거나, (ⅱ) 온혈동물에 패혈증 발현을 억제할 수 있는 조성물에 있어서, ㄱ) 검출할 수 없는 양의 2-케토-3-데옥시옥타노에이트, 인 약 350내지 475nmole/mg 및 지방산 약 1700내지 2000nmole/mg 을 함유하는 정제해독된 내독소와, (ㄴ)제약상 허용되는 담체와의 치료유효량으로 되어있는 것을 특징으로 하는 패혈증 발연억제조성물.
  12. 제11항에 있어서, 조성물이 인산염 완충생리식염수용액의 형태인 것을 특징으로 하는 조성물.
  13. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019850004992A 1984-07-12 1985-07-12 급성방사선 증후군 발현억제 및 패혈증 발현억제 조성물 KR880000191B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US630013 1984-07-12
US06/630,013 US4629722A (en) 1984-07-12 1984-07-12 Method of inhibiting the onset of acute radiation syndrome

Publications (2)

Publication Number Publication Date
KR860000867A true KR860000867A (ko) 1986-02-20
KR880000191B1 KR880000191B1 (ko) 1988-03-12

Family

ID=24525404

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850004992A KR880000191B1 (ko) 1984-07-12 1985-07-12 급성방사선 증후군 발현억제 및 패혈증 발현억제 조성물

Country Status (14)

Country Link
US (1) US4629722A (ko)
JP (1) JPS6193123A (ko)
KR (1) KR880000191B1 (ko)
AU (1) AU556971B2 (ko)
BE (1) BE902875A (ko)
CH (1) CH665355A5 (ko)
DE (2) DE3546592C2 (ko)
FR (1) FR2567403A1 (ko)
GB (1) GB2161381B (ko)
IL (1) IL75789A (ko)
IT (1) IT1214671B (ko)
NL (1) NL8501995A (ko)
NZ (1) NZ212691A (ko)
ZA (1) ZA855243B (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US5354782A (en) * 1991-01-17 1994-10-11 Merrell Dow Pharmaceuticals Inc. Polyamine phenols as radioprotective agents
US5530113A (en) * 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
AU660325B2 (en) * 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
DK2468300T3 (da) 2006-09-26 2018-01-29 Infectious Disease Res Inst Vaccinesammensætning indeholdende syntetisk adjuvant
TWI494125B (zh) 2009-06-05 2015-08-01 Infectious Disease Res Inst 合成的葡萄吡喃糖基脂質佐劑
SG194083A1 (en) 2011-04-08 2013-11-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
JP6619648B2 (ja) 2012-05-16 2019-12-11 イミューン デザイン コーポレイション Ｈｓｖ−２のためのワクチン
WO2017039751A1 (en) 2015-08-28 2017-03-09 Bioincept, Llc Mutant peptides and methods of treating subjects using the same
SG11201508092YA (en) 2013-04-18 2015-10-29 Immune Design Corp Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL295025A (en) * 2014-09-16 2022-09-01 Bioincept Llc Compositions and methods for treating acute radiation syndrome
CA2996874A1 (en) 2015-08-28 2017-03-09 Bioincept, Llc Compositions and methods for the treatment of neurodamage
KR101909660B1 (ko) * 2017-07-06 2018-10-18 이보미 안경알 자판기 서비스 제공 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1188519A (en) * 1966-10-27 1970-04-15 Wellcome Found Method for the Purification of Lipopolysaccharides
US4435386A (en) * 1982-05-26 1984-03-06 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
CA1225592A (en) * 1983-08-26 1987-08-18 Ribi Immunochem Research Inc. Refined detoxified endotoxin

Also Published As

Publication number Publication date
JPS6234733B2 (ko) 1987-07-28
CH665355A5 (de) 1988-05-13
KR880000191B1 (ko) 1988-03-12
IL75789A (en) 1990-04-29
FR2567403A1 (fr) 1986-01-17
US4629722A (en) 1986-12-16
AU556971B2 (en) 1986-11-27
IL75789A0 (en) 1985-11-29
DE3524992A1 (de) 1986-01-16
BE902875A (fr) 1985-11-04
GB8517545D0 (en) 1985-08-14
AU4475885A (en) 1986-01-16
ZA855243B (en) 1986-02-26
JPS6193123A (ja) 1986-05-12
DE3524992C2 (ko) 1988-05-11
NL8501995A (nl) 1986-02-03
GB2161381B (en) 1988-01-13
DE3546592C2 (ko) 1988-06-01
GB2161381A (en) 1986-01-15
IT8548347A0 (it) 1985-07-12
IT1214671B (it) 1990-01-18
NZ212691A (en) 1988-02-12

Similar Documents

Publication Publication Date Title
KR860000867A (ko) 급성 방사선 증후군 발현억제 및 패혈증 발현억제의 방법 및 그 조성물
MY100947A (en) External pharmaceutical composition.
ATE91233T1 (de) Antivirale pharmazeutische zusammensetzungen und ihrer verwendung.
MX163955B (es) Composicion farmaceutica de dihidrocodeina e ibuprofen
FI854127A0 (fi) Inositoltrifosfat.
KR860006464A (ko) 6-티오크산틴 유도체
ES2032905T3 (es) Sistema terapeutico transcutaneo.
IL92357A0 (en) Pharmaceutical compositions containing an antibacterial compound and an absorption enhancing system
SE8303003D0 (sv) Medel for att oka antitumorverkan hos antitumormedel
OA07525A (fr) Dérivés d'acides-animés, leur préparation et utilisation ainsi que les compositions contenant ces dérivés.
ES8307496A1 (es) Procedimiento para la obtencion de una preparacion galenica antagonista al calcio.
MX9203374A (es) Composicion farmaceutica que contiene l-alfa-glicerofosforilcolina.
DE3686022D1 (de) Monosaccharide enthaltende zusammensetzung zum heilen von wunden.
JPS5767518A (en) Radiosensitizing agent or agent for increasing effect of radiomimetic substance
KR900700448A (ko) 불포화 측쇄를 갖는 1α-히드로시비타민 D동족체
KR890004705A (ko) 항바이러스성 제제
AR007650A1 (es) Composicion farmaceutica para forma de dosis farmaceutica de gelatina blanda y forma de dosis que la comprende
ES460621A1 (es) Procedimiento de sintesis de n-(1'-alil-2'-pirrolidilmetil)-2,3-dimetoxi-5-sulfamoilbenzamida.
KR880004810A (ko) 소화성 궤양 치료제
KR830009776A (ko) 세포 보호 유도방법
KR850001696A (ko) 온혈동물의 보조제 응답유도 또는 면역응답 자극방법
DE3368199D1 (en) Mixture comprising a central analgesic and vitamin b12, or one of its analogs, as active principles
KR870011135A (ko) 시스-6-(4-아세트아닐리도)-8,9-디메톡시-2-메틸-1,2,3,4,4a,10b- 헥사이드로-벤조〔c〕〔1,6〕 나프티리딘으로 구성된 약학적 조성물 및 그것의 용도
KR880009656A (ko) 국소 치근막 질환의 치료 또는 예방법
SE8303719L (sv) Eburnan-oximderivat, forfarande for framstellning derav samt farmaceutiska kompositioner innehallande dessa foreningar

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19850712

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19850912

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19850712

Comment text: Patent Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19870707

Patent event code: PE09021S01D

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

Comment text: Decision on Publication of Application

Patent event code: PG16051S01I

Patent event date: 19880121

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19880525

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19880603

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19880603

End annual number: 3

Start annual number: 1

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee